These days, the chances of a life sciences company making it through the capricious initial public offering window frequently depends on the quality and quantity of their partnerships with larger pharmaceuticals companies.
These days, the chances of a life sciences company making it through the capricious initial public offering window frequently depends on the quality and quantity of their partnerships with larger pharmaceuticals companies.
